论文部分内容阅读
瑞士龙沙集团(以下简称“龙沙”)是全球烟酰胺领域当之无愧的主角。以市场占有率来衡量,国内65%以上市场份额、全球50%以上市场份额,足以证明龙沙在烟酰胺领域的地位。十几年来,龙沙在烟酰胺领域的王者身份无人质疑。从1995年进入中国市场,龙沙在烟酰胺行业的市场地位就已经根深蒂固。市场集中度高、供应格局稳定,原料被垄断一度是烟酰胺行业展现的特点,也是众多企业不堪竞争、不愿与龙沙正面为敌的最好借口。曾几何时,烟酰胺行业俨然烫手山芋,而由龙沙一家独大。然而,就从2008年开始,特别是进入2010年,随着国内企业的烟酰胺产品重要生产前体3-甲基吡啶技术取得突破,烟酰胺整个生产链条彻底打通,烟酰胺市场悄然发生着转变,市场供应格局蠢蠢欲动。那么,未来的烟酰胺市场发展趋势将会如何,作为当前行业老大的龙沙将会如何应对?带着这些疑问,《中国畜牧杂志》和“博亚和讯网”在北京国际VIV会议期间联合采访了龙沙(中国)投资有限公司营养原料业务总经理安纲先生。
Longshen Group (hereinafter referred to as “Longshao”) is a well-deserved protagonist in the field of nicotinamide in the world. Measured by market share, more than 65% of domestic market share and over 50% of global market share are sufficient to prove Longsha’s position in the nicotinamide field. Ten years, Longsha nicotinic acid in the field of identity no one questioned. From 1995 to enter the Chinese market, Lonza nicotinic acid in the industry’s market position has been deeply rooted. Market concentration is high, the supply pattern is stable, the monopoly of raw materials was once the nicotinamide industry to show the characteristics, but also many companies can not stand the competition, do not want to Lhasa positive enemy for the best excuse. Once upon a time, nicotinamide industry seems hot potato, but by the Lonza dominance. However, starting from 2008, especially into 2010, with the breakthrough of the 3-methylpyridine technology, an important precursor of nicotinamide products for domestic enterprises, the entire production chain of nicotinamide has been completely opened up and the market of nicotinamide has been quietly changed , The market supply pattern around the corner. So, the future trend of nicotinamide market will be how, as the leader of the current industry, how to deal with Lonza? With these questions, “China Animal Husbandry Magazine” and “Bo Ya He Network” during the Beijing International VIV meeting Jointly interviewed Mr. Liao Gang, general manager of nutrition raw materials business of Lonza (China) Investment Co., Ltd.